Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Analysis
Year: 2020
Type: article
Study design: Clinical Trial
Source: Blood
Authors: Christopher Melani, Rahul Lakhotia, Stefania Pittaluga, Milos D. Miljkovic, James D. Phelan, Jagan R. Muppidi, Craig J. Thomas, Michele Ceribelli, Frances Anne Tosto, Craig A. Portell, Rafic J. Farah, Seung Tae Lee, Anna Marie Juanitez, Seth M. Steinberg, Elaine S. Jaffe, Mark Roschewski, Louis M. Staudt, Wyndham H. Wilson
Institutions: National Institutes of Health, National Cancer Institute, Center for Cancer Research, National Center for Advancing Translational Sciences, University of Virginia, UPMC Hillman Cancer Center, University of Maryland, Baltimore, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2983242185